Journal
ONCOTARGET
Volume 8, Issue 28, Pages 46461-46467Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.17518
Keywords
phosphodiesterase type 5 inhibitors; malignant melanoma; basal cell carcinoma; meta-analysis; systematic review
Categories
Funding
- Second Affiliated Hospital, Wenzhou Medical University
Ask authors/readers for more resources
Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03-1.21, I-2 = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available